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Abstract
 
Pulmonary surfactant proteins SP-A,B,and Cwere studied in mice
 
exhibiting diabetes mellitus. TypeI diabetes mellitus wasproduced via injection
 
ofstreptozotocin(STZ)in C57BL/KsJ db/m mice. Genetically diabetic
 
C57BL/KsJ db/db mice were used asa modelfor type 11 diabetes mellitus. The
 
mice were also grouped based on age asimmature and mature. Lung lavage was
 
collected and sodium dodecylsulfate polyacrylamide gel electrophoresis
 
(SDS-PAGE),Western blotting,and immunostaining were performed to
 
characterize the proteins. EndoglycosidaseFand neuraminidase type X were used
 
to assess the degree ofprotein glycosylation. The results confirmed the presence
 
ofSP-Ain36 and 43kDa sizes,and identified SP-B/C as a 14 and 72kDa protein
 
in the mouse. Deglycosylation with endoglycosidaseFand neuraminidase
 
confirmed thatSP-A had been glycated with mannose and sialic acid. No
 
phenotypic difference in molecular weightsforSP-A wasfound between type I
 
diabetic and vehicle-treated mice,and typen diabetic and normal mice. However,
 
the relative amountofSP-A wasless in type 11 diabetic animals than in normal
 
animals(0.70 +.0.49 ug versus 1.74 +.1*01 ug,P^O.05). Age-related increases for
 
the molecular weights ofSP-A within the phenotypes and treatment groups were
 
presentand appeared to be caused by protein glycosylation.
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Chapter 1: Introduction
 
Much ofthe prior investigation regarding pulmonary surfactant has
 
centered around factors which affectthe biosynthesis ofthe lipid components,
 
primarily dipalmitoyl phosphatidylcholine(DPPC),phosphatidylglycerol(PG),
 
phosphatidylinositol(PI),and sphingomyelin(S)(1-11). However,more recent
 
investigation hasinvolved the study ofapoproteins present asasmallpercentage
 
ofthe total surface-active mixture,surfactant proteins A,B,and C(SP-A,SP-B,
 
SP-C). These apoproteins are thought to aid extracellular type II pneumocyte
 
lipid transport and increase the adsorption ofthe lipid portion ofthe pulmonary
 
surfactant to the alveolar interface,thusforming a primary link between the
 
alveolus and the surface-tension-reducing lipids.
 
SP-A,the quantitatively predominant protein,is presentin a diversity of
 
mammalian species(12),hasa basic pH(12-16),and hasa monomeric molecular
 
weight(Mr)ofbetween26and 36kDa(12-14,17-20). Generally,this range of
 
molecular weights is thought to be due to variable degrees ofpost-translational
 
glycosylation which influences protein mobility during polyacrylamide gel
 
electrophoresis(PAGE). Studies ofglycosylation show neuraminidase- and
 
endoglycosidase-sensitive forms which indicate the presence ofsialic acid and
 
mannose moieties on the rat,dog,and human protein core(13-18,21-25). RatSP­
A also contains disulfide bonds which appear to be required for biological activity
 
(18,26,27). Synthesis ofSP-A is dexamethasone-(28-30)and cAMP-inducible(22)
 
in humans and rabbits,respectively,and has beenidentified in alveolar and
 
bronchiolar cells(15,16,21,24,31-34). While it was originally thought thatSP-A
 
mightfunction with the surfactantlipids to increase alveolar adsorption,recent
 
findings reveal that this is notthe case(35,36). Rather,SP-A acts with the divalent
 
cation calcium to increase lipid aggregation as evidenced byincreased Uposome
 
clustering(37,38). These results have led to the present hypothesis that the
 
primaryfunctions ofSP-A are to act as a transportligand to direct surfactantlipids
 
to type II pneumocytes and to increase lipid uptake by type 11 pneumocytes(39).
 
Regulation ofsurfactant turnover appears to be the main physiological role of
 
SP-A.
 
While thelower molecular weight surfactant proteins,SP-B and SP-C,have
 
been studied less extensively,more information has recently become available.
 
SP-B in reduced forms appears as an8kDa monomerin the pig and a 16kDa
 
form in the rat(40). It also has multiple hydrophobicsequences and intrachain
 
cysteine-containing disulfide bonds(41). SP-Cis encoded on chromosome8in
 
hmnans(42)and has a monomeric molecular weight of5-6kDain the cow,rat,
 
and human(32,43-45). It contains valine-,phenylalanine-(45),leucine-,and
 
isoleucine-rich(46)hydrophobic amino acid sequences. Intracellularly,SP-Cis
 
contained in lamellar bodies within the alveolar cells(46). These proteins are
 
believed to be responsible for enhancing lipoalveolar adsorption and reducing
 
alveolar surface tension as evidenced by surface balance measurements(36,47-49).
 
These effects have been reported to increase arterial oxygenation(Pa02),
 
decrease pulmonary inflation pressures,and increase lung compliance(48). Since
 
SP-B and SP-C appear to play animportant role in alveolar patency,and thus in
 
pulmonary physiologicfunction,greater research is now being undertaken to
 
determine not only their functional characteristics but whether they play an
 
etiologic role in various pathophysiologic conditions.
 
Researchers have begun to investigate the effect ofmetabolic disturbances
 
such as diabetes mellitus on the surfactant proteins. When amniocentesis was
 
performed to deduce fetal pulmonary status in controlled maternal diabetes
 
mellitus compared with nondiabetic patients,no significant difference wasfound
 
(50). However,when the study wasrepeated for uncontrolled maternal diabetes,
 
SP^A quantity wasless in diabetic patients than in nondiabetic patients(51). Total
 
amnioticSP concentration was also assayed for use as anindicator ofpulmonary
 
maturity,and reportedly correlates better than previously used indices such as
 
lecithin/sphingomyelin(L/S)ratios(52). Clinically,diabetic patients have
 
reduced arterial oxygenation(Pa02)and pulmonary diffusion capacities(DlCO)
 
when compared with nondiabetic patients. These results are consistent with
 
alveolar collapse,and hence have been attributed to a possible functional
 
alteration in surfactant(53),such as a deficiency and/orfunctional changein
 
apoproteins. In addition,Alloxan-induced diabetic rats showed decreased
 
surfactant proteins,which has been attributed to possible changesin lung protein
 
or carbohydrate metabolism(40).
 
Uncontrolled typeIand type II diabetes produce an absolute or relative
 
lack ofinsulin,respectively,which leads to hyperglycemia. In addition,
 
type I-associated hypoinsulinemia decreases amino acid transportinto cells,
 
reduces transcription and translation,and increases protein catabolism(54). Such
 
alterations in protein and carbohydrate metabolism,when combined with the fact
 
that surfactant proteins are glycosylated post-translationally,make it likely that
 
diabetes may alter surfactant proteins via changesin biosynthesis and/or
 
glycosylation.
 
While SP-A has beenidentified in mice(12,31,55)and has beenfound to
 
have multiple isoforms with isoelectric pointsfrom 4.4-5.6(12),studies to
 
determine the basisfor the heterogeneity ofthe proteinin this species have not
 
been performed. Surfactant proteinsB andChave notbeen identified nor
 
characterized in the mouse.
 
The objectives ofthis study were to examine the surfactant proteinsin
 
terms of molecular weightand quantity in the presence oftype I(insulin­
dependent)and type II(noninsulin-dependent)diabetes mellitus. The
 
C57BL/KsJ db/db diabetic mouse,Mm mmculm,serves as a modeloftype II
 
(noninsulin-dependent diabetes melhtus)because it exhibits hyperglycemia,
 
hyperinsulinemia,hyperphagia,and obesity(56). The modelwas used to assess
 
the possibility ofnonenzymatic glycation ofsurfactant proteins in the presence of
 
insulin. Heterozygous C57BL/KsJ db/m littermates which do not exhibittype II
 
diabetes mellitus,were used as nondiabetic control animals. To assess the
 
possibility ofnonenzymatic glycation ofsurfactant proteins in the hypoinsulinemic
 
and hyperglycemic mouse,heterozygous C57BL/KsJ db/mmice were injected
 
with streptozotocin(STZ)to selectively destroy pancreatic beta cells and reduce
 
serum insulin levels. Therefore,the effect ofhyperglycemiain the presence and
 
absence ofinsulin on surfactant protein glycosylation and quantity wasinvestigated
 
using these two models. Different ages ofmice were examined to permit varying
 
periods ofexposure to high levels ofserum glucose to ascertain whetherlength of
 
exposure to hyperglycemia influenced the degree ofprotein glycosylation.
 
Therefore,the purpose ofthis investigation was to confirm the presence of
 
SP-Ain the C57BL/KsJ mouse,to ascertain whether SP-B and SP-C were
 
present,to discern to whatextent post-translational glycosylation ofthese proteins
 
occurred,and to evaluate the effect oftype I and type II diabetes on these
 
surfactant proteins.
 
Chapter2:Materials and Methods
 
ExperimentalAnimals
 
Homo2ygoiisC57BL/KsJ db/db mice were used as a modelfor type 11
 
diabetes mellitus while heterozygous(db/m)littermates served as nondiabetic
 
control animals. Streptozotocin(STZ)wasused to induce type Idiabetes via
 
intraperitoneal injection(0.008 ml/g,STZ/Citrate-NaCl70mg/ml,0.05 M
 
Citrate,0.15 M NaCl,pH4.5)following 24-hourfasting in eight-week-old non-

diabetic C57BL/KsJ db/m mice. Heterozygous C57BL/KsJ db/m mice injected
 
with vehicle(0.05 M Citrate,0.15M NaCl,pH4.5)were used as control animals.
 
Mice werefurther grouped as either immature(8-12weeks ofage),or mature
 
(over 12weeks ofage)to representearly or stable long-term diabetes,
 
respectively. Fiveimmature and five mature animals were included for study in
 
each ofthefollowing groups: untreated nondiabetic,vehicle-treated nondiabetic,
 
untreated type II diabetic,and STZ-induced typeI diabetic. Each group was
 
housed at23-27®C,30-60% relative humidity,in6X9X 12-inch shoebox cages
 
on hardwood chip bedding. Automatic lighting furnished 14 hours oflight and 10
 
hours ofdark per day. Food and water were provided ad libitum.
 
LavageProcedure
 
Mice were anesthetized with Nembutal(50mg/ml,60mg/Kg body weight,
 
intraperitoneally)and their lungslavaged with 1.0 mlof0.9% NaCl. After
 
confirming the anesthetic plane via extinction ofthe corneal reflex,a cervical
 
dislocation wasperformed and an incision madein the abdominal walljust below
 
the anterior rib cage and extended laterally until the diaphragm was visible. A
 
diaphragmatic puncture wasthen performed to allow visualization ofthe lungs.
 
Anincision was made in the neck approximately overlying the thyroid cartilage.
 
and the musculature dissected away until the trachea was visible, after which a 1.0
 
mmtracheotomy was made and a22-gauge X 1inch Teflon angiocatheter(Becton
 
Dickinson)inserted approximately 0.5 inch into the tracheallumen. After ligating
 
the angiocatheter in place,a 1.0 mlsyringe containing 0.5 mlof0.9% NaClwas
 
attached to the angiocatheter and used to lavage the lungs. Each sample was
 
injected into and withdrawnfrom the lungstwo times,quantified for recovered
 
volume,and stored in an ice bath. Thelavage samples were then centrifuged at
 
1500RPM(500Xg)for 15 minutes at4®Cin aBeckman AccuspinFR centrifuge
 
to remove cells and debris. The resultant supematants were transferred to 1.5 ml
 
polypropylene microcentrifuge tubesfor storage at-80®C.
 
Quantitation ofBlood Glucose
 
Just prior to the lavage procedure,blood was obtained via cardiac puncture
 
for the determination ofserum glucose. The blood was obtained with an
 
unheparinized 1 mlsyringe and transferred to microcentrifuge tubes which were
 
placed at4°'Cfor 1 hour to allow clotting. After coagulation,the blood was placed
 
in aBeckman centrifuge and spun at 1500RPM(500xg)for 15 minutesto
 
separate the serum and nonserum components. Serum was transferred to fresh
 
microcentrifuge tubes and stored at-20°C. Serum glucose(in mg/dL)was
 
determined by hexokinase colorimetric method(Sigma diagnostics).
 
Apoprotein Preparation and Analysis
 
Protein separation was performed viasodium dodecylsulfate
 
polyacrylamide gel electrophoresis(SDS-PAGE)on15%gels(Laemmli)with
 
Hoefer Scientific Instruments(HSI)MightySmallSE-250vertical slab gel units.
 
A100ulsample ofeach lavage was evaporated to dryness using a Savant
 
Speed-Vac(ModelSVCIOOH)and resuspended in 15 ul oftreatment buffer
 
(0.125 M Tris,4%SDS,20%Glycerol,10%2-Mercaptoethanol,pH 6.8).
 
Molecular weight standards(Sigma diagnostics,#MW-SDS-70L)were added in a
 
gellane during each run to allow interpolative calculation ofthe molecular weights
 
ofthe unknownsamples,as follows: bovine serum albumin(BSA),66kDa;
 
ovalbumin,45kDa;glyceraldehyde-3-phosphate dehydrogenase,36kDa;carbonic
 
anhydrase,29kDa;trypsinogen,24.1 kDa;trypsin inhibitor,20.1 kDa;alpha­
lactalbumin,14.2kDa;and arange ofmyoglobinfragments(Sigma diagnostics,
 
#MW-SDS-17)from 6.21 to 16.95 kDa(Myoglobin backbone,16.95 kDa;
 
fragmentsIand II, 14.4 kDa;fragmentI,8.16kDa;fragmentII,6.21 kDa).
 
Resuspended lavage samples were heated to lOO^Cfor3minutes prior to
 
loading the gel. Ten microliter(10ul)volumes were loaded into the wells using a
 
Pipetman micropipet,and asmallvolume ofbromphenolblue(BPB)tracking dye
 
was added to each sample to aid visuahzation. Constant current gel
 
electrophoresis was performed(20 mA/gel)at4®Con each gelin tank buffer
 
(0.025 M Tris,0.192M Glycine,0.1%SDS,pH8.3)until the BPB tracking dye
 
frontreached the bottom ofthe gel(approximately 1 hour/gel).
 
Protein identification wasconfirmed via staining with Coomassie Brilliant
 
Blue R-250(0.125%in Methanol/Acetic Acid)for30 minutes,followed by
 
destaining in50% Methanol/10% Acetic Acid(DestainI)for one hour,and5%
 
Methanol/7% Acetic Acid(Destain II)to term.
 
Specific identification ofsurfactant proteins was by Western blotting
 
following electrophoretic transfer ofgel-separated proteins using an HSITE-42
 
transfer apparatus. Samples which were electrophoresed into the Laemmligel
 
matrix butnotstained were electrophoretically transferred in 0.025 M Tris,
 
0.192M Glycine,20% Methanol,pH8.3to nitrocellulose(Micron Separations
 
Inc.,Nitroplus 2000). Biotinylated molecular weightstandards(phosphorylase B,
 
97.4kDa;bovine serum albumin,66.2kDa;ovalbumin,45kDa;carbonic
 
anhydrase,31 kDa;soybean tiypsin inhibitor,21.5 kDa;and lysozyme,14.4
 
kDa)(Biorad)were added to a gellane during each run to allow calculation of
 
molecular weights after Western blotting. The unstained gels were layered in the
 
transfer apparatus after uniform soaking ofblotter paper,nitrocellulose,gels,and
 
spongesin transfer buffer. This apparatus wasthen placed in the transfer chamber
 
with the nitrocellulose closest to the cathode,the transfer chamber filled with
 
buffer,and electrophoresed at a constant250V at4°Cfor2hours. After the
 
transfer,the nitrocellulose wasremovedfrom the apparatus and transferred to
 
self-sealing plastic containersfor theimmunostain procedure. The proteins were
 
then labeled with either rabbit-anti-human SP-A or rabbit-anti-bovine SP-B/C
 
polyclonalantisemm(provided byDr.William Taeusch,Dr.Alan Waring,and Dr.
 
B.R.Fan,King/Drew Medical Center,Los Angeles,Ca.).
 
Immunostaining ofthe proteins transferred to the nitrocellulose took place
 
in the following manner. In the case ofthe SP-A blots,the nitrocellulose was
 
submersed inBLOTTO(5%w:v Carnation nonfat dry milk in tris buffered saline
 
{TBS})at37®C with shakingfor2hours to block nonspecific protein binding.
 
After discarding the old BLOTTO, polyclonal rabbit antibody to SP-A was added
 
to the nitrocellulose(1:1000in BLOTTO;50ul:50 ml)and incubated atroom
 
temperature with shaking overnight(12-18 hours). After discarding the
 
BLOTTO/surfactant-antibody mix,the nitrocellulose was rinsed with fresh
 
BLOTTO three times at37®C with constantshaking,10 minutes per rinse.
 
Biotinylated goat-anti-rabbitIgG(Sigma)(l:10,000in BLOTTO;5ul:50 ml)was
 
added and incubated for2hours at37®C with shaking,after which the
 
nitrocellulose wasrinsed three times with TBSfor ten minutes each at37®C with
 
shaking. A 1:1000(50ul:50 ml)mix ofAvidin horseradish peroxidase(AvHRP;
 
Biorad)inTBSwas next added and incubated for2hours at37®C with shaking,
 
after which the blot was rinsed three times with TBSover 10minutes atroom
 
temperature. After discarding the TBS rinse,60mg of4-Chloro-l-Napthol in 20
 
mlMethanoland60ulof30%H202in 100mlofTBSwere mixed and added to
 
the blot atroom temperature and allowed to colorize. Theimmunostain
 
procedurefor the SP-B/C blots was essentially identical to the SP-A blots with two
 
modifications. The nitrocellulose was initially blocked with a1%preparation of
 
gelatin/TBS,and the polyclonal rabbit anti-bovine SP-B/C antibody was
 
incubated at37®C with shaking in 1:1000(50ul:50 ml)1%gelatin/TBS. Positive
 
identification and location ofthe surfactant apoproteins on nitrocellulose resulted
 
in blue-colored bands indicative ofantibody/protein binding. These bandswere
 
compared to simultaneously run CBB-stained gelsfor identification,analytical
 
determinations,and positional referencing within the total banding pattern.
 
To ascertain the extent ofsurfactant protein glycosylation,additional gel
 
electrophoretic runs were performed onlavage samplesfollowing the addition of
 
neuraminidase type X(Sigma diagnostics,#N-2133)and endoglycosidaseF
 
(Sigma diagnostics,#E-1262)to remove the sialic acid and mannose groupsfrom
 
the protein core.
 
Neuraminidase(0.3 units/ml)in0.2M Tris-Cl,0.1% NonidetP-40,pH7.4
 
was added to the untreated lavage sample(10-50ug total protein)and incubated
 
at37®C with constantshakingfor 18 hours prior to SDS-PAGEand Western
 
blotting. Before treatment with EndoglycosidaseF(0.2units/assay),the untreated
 
lavage sample wasadded to50ul solubilization buffer(100mM NaH2P04,50
 
mMEDTA,1.0%SDS,pH6.1),and heated at95®Cfor3minutes. Three
 
microliters ofEndoglycosidaseFin20mMPotassium Phosphate,50mMEDTA,
 
Sodium Azide,pH 7.2,and 10ul of10%Triton X-100were then added to the
 
sample before incubating4hours at37®C with shaking, SDS-PAGEand Western
 
blotting ofthe samples were then performed as previously described.
 
Deglycosylated samples were then compared to originalsamplesfor
 
determinations of molecular weights.
 
Stained gels and immunoblots were assessed for optical density and
 
position ofeach band using a BioRad 620 Video densitometer. Protein bandingin
 
samplelanes and molecular weightstandard lanes was evaluated positionally via
 
the calculation ofrelative mobility(Rm). A plot ofRm values on the abscissa
 
versus naturallog(In)molecular weight on the ordinate was performed with aline
 
ofleastsquares drawn. SubsequentRm values were then calculated for surfactant
 
protein bands and compared against the line ofleast squares ofIn molecular
 
weight standardsfor interpolation ofmolecular weight. Densitometric
 
measurementoftotal optical density per lane was used,in combination with the
 
Coomassie Brilliant Blue method total protein assay(Spectrum,#132920),to
 
quantitate total protein concentration in lavage and relative protein
 
concentrations ofsurfactant proteins.
 
Data Analysis
 
Statistical evaluation ofdata was by analysis ofvariance and the Student­
Newman-Keulsrange test(57). Regression analysis wasperformed using Lotus
 
1-2-3(Lotus Corporation).
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Chapter3; Results
 
Serum Glucose
 
Values ofserum glucose for untreated normaland diabetic mice are listed
 
in table I. Immature and mature normal mice had significantly lower levels of
 
glucose than their type II diabetic counterparts(191.5±_ 88.7 mg/dlversus
 
486.0±.184.1 mg/dl;P^O.05). Within each phenotype,there were no significant
 
differences in blood glucose between age groups. Blood glucose comparisonsfor
 
the type I diabetic(STZ-treated)and vehicle-treated groupsshowed no significant
 
differences(Table II).
 
Characterization ofPulmonary Surfactant Apoproteins
 
SDS-PAGE(Figure 1)followed by Western blot and immunostaining
 
(Figure2)ofmouse lung lavage with polyclonal antibody to SP-A characteristically
 
revealed four bands(B1-B4)having molecular weights ofapproximately 91,77,45,
 
and 35kDa,respectively. When mouse serum wassubjected to thesame
 
procedures,two bands comigrated and were visualized,corresponding to bandsBi
 
and B2ofmouse lung lavage(Figure 3).
 
Blotting and immunostaining ofnormal mouselunglavage with polyclonal
 
antibody to SP-B/C revealed two major bands with molecular weights of
 
approximately 14 and 72kDa(Figure 4)with no evidence ofcross reactivity to
 
mouse serum. A more complete characterization ofSP-B/Cwasinconclusive due
 
to inconsistentimmunostaining results.
 
Phenotypic comparison ofSP-A bandsBythrough B4showed no significant
 
molecular weight differences between normaland type II diabetic subjects
 
(Table III). However,age-related comparisons within each phenotype revealed a
 
significant increase in the molecular weightsfor B3and B4when comparing
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Table 1. Serum Glucoseinl^eII Diabetic Mice versus Normal Mice
 
Serum Glucose(mg/dl)
 
Normal(Immature) 159.2 ± 
(5) 
33.2^ 
Normal(Mature) 223.8 ± 
(5) 
118.2^ 
Diabetic(Immature) 585.6 ± 197.0^
 
(5)
 
Diabetic(Mature) 386.4 ± 112.4b
 
(5)
 
Normal(Immature and Mature) 191.5 ± 88.7^
 
(10)
 
Diabetic(Immature and Mature) 486.0 ± 184.1^
 
(10)
 
Values are Mean + S.D,
 
Treatmentgroups having different superscripts are
 
statistically distinguishable atP^0.05
 
Numberin parentheses denotes number ofsamplesin
 
group
 
Table II. Serum Glucose in Streptozotocin(STZ)-Induced
 
Diabetic Mice versus Vehicle-Injected Mice
 
Serum Glucose(mg/dl)
 n
 
STZ 135.6 ± 58.4^ 10
 
Vehicle 219.6 + 140.9^ 9
 
Values are Mean S.D.
 
n denotes number ofsamplesin group
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Figure 1. Coomasssie Brilliant Blue Gels - Bands1through4in T^pe II Diabetic
 
versus Normal Mice. Coomassie Brilliant Blue-stained gels oflung lavage
 
representing immature and mature type II diabetic mice and iiormal mice. Bands
 
Bi through B4 are labeled corresponding to SP-A,with B5 corresponding to SP­
B/C. Molecular weights standards: bovine serum albumin,66kDa;ovalbumin,45
 
kDa;glyceraldehyde-3-phosphate dehydrogenase,36kDa;carbonic anhydrase,29
 
kDa;tiypsinogen,24.1 kDa;trypsin inhibitor,20.1 kDa;myglobin backbone,16.95
 
kDa; uiyoglobinfragmentsI and II, 14.4 kDa;alphalactalbulnin,14.2kDa;
 
myglobinfragmentI,8.2kDa;and myglobinfragmentII,6.2kDa(lane 1).

Immature normal mouse(in)(lane 2),immature diabetic mouse(id)(lane 3),
 
mature normal mouse(mnXlane 4),and mature diabetic mouse(m^j)(lane 5)are
 
shown.
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Figure2. Immunostaln ofSP-A-l^pe II Diabetic versus Normal Mice.
 
Immunostain ofbandsBi through B4representing SP-Ainimmature and mature
 
type II diabetic mice and normal mice. Biotinylated molecular weightstandards;
 
(phosphorylase B,97.4 kDa;bovine serum albumin,66.2kDa;ovalbumin,45kDa;
 
carbonic anhydrase,31kDa;soybean trypsin inhibitor,21.5 kDa;and lysozyme,
 
14.4 kDa)(lane 1). Immature normal mouse(in)(lane 2),immature diabetic
 
mouse fidXlane 3),mature normal mouse(mij)(lane 4),and mature diabetic
 
mouse(m^)(lane 5)are shown.
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Figure 3. Immuuostain ofSP-A- MouseSerum versus Lung Lavage. SP-A
 
serum and lung
 
. r ^ -^,97.4
 
kDa;bovine serum albunm,66,2kDa;ovalbumln,45kDa;carbonic anhydrase,31
 
kDa;soybean trypsin inhibitor,21,5 kDa;and lysozyme,14,4 kDa), Bands Bi and
 
B2representing anti-SP-A inmiunostained mouse serum appear in lane2, Bands
 
Bi(91 kDa),B2(77kDa),B3(45l^a),and B4(35kDa)from mouse lung lavage
 
immunostained with anti^SP-A antibodyare showninlane3,
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Figure4. Immunostain OfMouse SP-B/C. Iminunostain ofbandsrepresenting
 
SP-B/Cin the C57BL/KsJ db/m mouse. Biotinylated molecular weightstandards
 
(lane l)(phosphorylase B,97.4 kDa;bovine serum albumin,66.2kDa;ovalbumin,
 
45 WDa;carbonic anhydrase,31kDa;soybeantrypsin inhibitor,21.5 IdDa;and
 
lysozyme,14.4 kDa). SP-B/C is represented by 14kDa and 72kDa bandsin lane
 
2whose position is highlighted by the asterisks.
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 Table III, SP-A Molecular Weight Comparison(kDa)in T^peTl Diabetic Mice
 
Immature
 
Group
 
Normal
 
Diabetic
 
Mature
 
Group
 
Normal
 
Diabetic
 
versus 
Normal Mice
 
Bl
 
85.6^
 
+ 3.32
 
(5)
 
92.3^
 
+ 6.42
 
(5)
 
92.3^
 
+ 6.93
 
(4)
 
95.3^ 'V
 
5.59 >
 
Band
 
B2
 
70.0^
 
+ 4.29
 
(5)
 
74.5^
 
+ 7.21
 
79.3^
 
83.0^
 
2.62
 
B4
 
34.6^
 
+ 1.9
 
(5)
 
36.0f
 
+ 1.31
 
(5)
 
46.28
 
+1.42
 
(5)
 
46.78
 
+ 0.55
 
(5)
 
. + 

(5) (5)
 
Valuesreported are Mean±S.D.
 
Number of samples in group in parentheses
 
Values having different superscripts are
 
statistically distinguishable atP^O.05
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B3
 
42.6 d
 
+ 2.21
 
(5)
 
43.0^
 
+ 2.05
 
(5)
 
54.9®
 
+ 0.86
 
(5)
 
55.4® 5
 
+ 1.41
 
(5)
 
immature with mature mice(Table III). Valuesfor B3inimmature mice were
 
42.6 +.2.21 kDain normal animals,and 43.0±.2.05 kDain diabetic mice as
 
compared to 54.9 +.0.86kDaand 55.4±_ 1.41 kDa,respectively,for their mature
 
counterparts(P^0.05). B4valuesinimmature mice were 34.6±_ 1.9kDain
 
nondiabetic,and 36.0 +_ 1.31 kDafor diabetic mice,versus46.2 +.1.42kDaand
 
46.7 +.0.55 kDa,respectively,for mature mice(P^0.05).
 
Glycosidase cleavage resulted in the reduction ofthe molecular weights of
 
SP-A bands which were stained positively by the anti-SP-A antibody(Figure 5).
 
The addition ofneuraminidase typeXreduced the molecular weight ofB3and B4
 
by approximately2kDa. Comparison ofdeglycosylation,using endoglycosidase F,
 
between normaland type II diabetic mice showed a reduction in molecular weight
 
from 46.1 to 44.2kDain normalsubjects as compared to 48.5 to 44.2kDafor
 
diabetic mice.
 
Protein assaysfor totallavage,absolute SP-A quantity,and relative SP-A
 
quantityfor type II diabetic versus normal mice are listed in table IV. Totallavage
 
protein waslessin diabetic thanin normal animals(10.17i6.27ug versus 16.17
 
±_ 8.42ug,P^0.05),as was the absolute amountofSP-A(0.70jL 0.49ug versus
 
1.74 +.1.01 ug,Pj<0.05)and the relative amountofSP-A(10.38 +.3.49%
 
compared to 19.38 +_ 10.64%,P^0.05). While differences in percentSP-A were
 
notsuppported statistically between type I diabetic and vehicle-treated groups
 
(immature: type 118.1%versus vehicle 21.1%,and mature: type 111.8%versus
 
vehicle 11.0%),the mature subjects ofeach group appeared to have lower relative
 
amounts ofSP-A than their younger counterparts.
 
Within-group serum glucose levels were inconsistentin the streptozotocin­
and vehicle-treated subjects for determination oftypeI diabetes(Table II). While
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Fij^re 5. Post-glycosidase Immunostain ofMouse SP-A. Biotinylated molecular
 
weight standrnds(lane l)(phosphorylase B,97.4kba;bovine serum albumin,66.2
 
kDa;oyalbumin,45kDa;carbonic anhydrase,31kDa;soybean trypsin inhibitor,
 
21.5kDa;and lyso2yme,14,4 kDa). Untreated mouselunglayage(B345kDaand
 
B437kDa)(lane 2). Mouse lung lavage treated with neuraminidse typeX(lane
 
3)(B343kDaand B435 kDa). Mouselung lavage treated with endoglycosidase F
 
(lane 4)(B342kDaand B435 kDa).
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TableIV. Quantitation ofPulmonary LavageProtein(SP-A)inl^eII Diabetic
 
and Normal Mice
 
Group
 
Total Normal 16.17 ± 8.42ug
 
Protein (6)
 
Diabetic 10.17 +. 6.27ug
 
(6)
 
SP-A Normal 1.74 ± 1.01 ug*
 
Absolute (6)
 
Diabetic 0.70 ±_ 0.49 ug
 
(6)
 
Percent Normal 19.38 ± 10.64%*
 
SP-A (6)
 
Diabetic 10.38 ± 3.49%
 
(6)
 
* Indicates significant difference(P:<0.05)
 
between normaland diabetic group
 
Values are MeaniS.D.
 
Number ofsamplesin parentheses
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no difference wasfound between streptozotocin- and vehicle-treated micein terms
 
ofthe molecular weights ofbands 1 through 4,an age-related increase was
 
exhibited between bands3and4within each group(Table V). Valuesfor B3in
 
immature vehicle-treated mice were 40.1±,2.66kDa ascompared to 47.2 +_ 2.39
 
kDa(P^O.05)for their mature counterparts,while valuesforB3inimmature
 
streptozotocin-treated mice were 43.6 +.5.63kDaversus50.8 JL3.10kDa
 
(P^0.05)for the mature mice. B4 molecular weightsfor immature vehicle- and
 
streptozotocin-treated groups were 35.2 1.87kDaand 35.4 +_ 2.83 kDa,
 
respectively,versus 39.6i2.62kDaand 41.7 +.3.34kDafor the mature subjects
 
(P^0.05). Correlation coefficients for molecular weight versusserum glucose
 
showed no correlation between these parameters(r- 0.07B;i;r=0.16B2;r=0.44
 
B3;r=0.50B4).
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Table V. SP-A Molecular Weight Comparison(kDa)in TypeI Diabetic Mice
 
versus Vehicle-Treated Mice
 
Band
 
Immature Group B2 B4
B3
 
Vehicle 74.6^ 61.1^ 40.1^ 35.2®
 
+ 4.92 + 3.63 + 2.66 + 1.87
 
(5) (5) (5) (5)
 
TypeI 75.6^ 63.3^ 43.6^ 35.4®
 
Diabetic + 8.12 + 4.80 + 5.63 + 2.83
 
(5) (5) (5) (5)
 
Mature Group
 
Vehicle 75.4a 63.1^ 47.2^ 39.6f
 
+ 11.92 + 7.09 + 2.39 + 2.62
 
(4) (4) (4) (4)
 
TypeI 77.3^ 65.4 b 50.8^ 41.7^
 
Diabetic + 5.82 + 4.14 + 3.10 + 3.34
 
(5) (5) (5) (5)
 
Values reported are MeaniS.D.
 
Number ofsamplesin parentheses
 
Values with different superscripts are statistically
 
distinguishable at?:<0.05
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Chapter4: Discussion
 
Other investigators have reported a group ofproteinsfrom60to65kDain
 
mouse lunglavage which are labeled byimmunoblotting with anti-SP-A antibody
 
(12). The results ofthis study comparing theimmunostain ofmouseserum and
 
lung lavage with polyclonal anti-SP-A antibodyshow cross-reactivity ofmouse
 
serum with this antibody at similar molecular weights corresponding to bands 1
 
and 2. In addition,post-glycosidase molecular weights ofBjand B2reported in
 
this study correlate with molecular weights reported for serum albumin in other
 
investigations(58). This indicates possible serum contamination ofthe original
 
SP-A used as an antigen whentheSP-A anitbody was prepared,or comigration of
 
serum and lavage proteins ofsimilar molecular weights which are not resolved by
 
one-dimensionalPAGE. Thus,the resulting bands appearing asBl and B2on
 
anti-SP-A blots likely representserum contaminants ofthe lung lavage. Ifso,
 
these are mostlikely present as aresult ofthe surgical procedure used to obtain
 
the lung lavage,or due to transudation offluid across the alveolar capillary
 
membranefrom pulmonary capillaries during the lavage. Ifthese higher
 
molecular weight bands are SP-A,then they may represent a dimericform ofthe
 
protein or aform in various stages ofpost-translational modification.
 
While B]^ and B2mayrepresentserum proteins,the absence ofcross-

reactivity between mouseserum and bands3and4indicate that these are not
 
serum contaminants. Indeed,the molecular weights of35kDaand 43kDafor
 
immature normaland diabetic mice reported here for these bands substantiate
 
findings by other investigators regarding the molecular weight ofSP-A(12).
 
The results ofthis investigation,showing a reduction in molecular weight of
 
SP-A using neuraminidase type X and endoglycosidase F,support studies ofother
 
species involving SP-A glycosylation in which sialic acid and high mannoseforms
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were cleaved from the protein core via treatment with these glycosidases(IS
 
IS,21-25). Nonenyzmatic glycation ofproteins has been reported in diabetes
 
(59,60)and is reported to be possible in any protein with afree-reacting lysine or
 
valine in the presence ofglucose(59). This effect has beenfound to alter protein
 
function(61)and possibly play a role in various complications ofdiabetes through
 
deactivation ofenzymes,decreased proteolysis,and alteration ofregulatory
 
molecules(60^62). While no difference between phenotypes was observed in this
 
study regarding the molecular weights ofSP-A,asignificant increase in molecular
 
weight ofSP-A was evident betweenimmature and mature subjects within each
 
phenotype. Since treatment with endoglycosidaseFreduced these heterogeneous
 
weights to acommon value ofapproximately 44,2 kDa,glycosylation ofthe protein
 
core mightbe the cause for this age-related alteration. However,since there was
 
no phenotypic difference between normoglycemic and hyperglycemic animals,it
 
seemslikely that the glycosylation is independent ofintravascular serum glucose
 
levels and involves intracellular processing and glycosylation consistent with Golgi
 
bodyfunction. Although studies to date have notbeen performed to deduce the
 
amino acid sequencefor mouseSP-A to determine whether the free-reacting
 
amino acids valine or lysine are present,bovine,canine,and human surfactant
 
proteins have beenfoimd to contain valine(45). Considering the importance of
 
these proteins,phylogenetic conservation mightsuggest that mouse surfactant
 
proteins also be expected to contain valine.
 
It has been reported that nonenzymatic glycosylation ofserum albumin
 
occurs ata higher levelin diabetics than in nondiabetic individuals(58),and that
 
its measurementis anindex for short-term diabetic control. Since bands 1 and2
 
ofthe immunoblots mayin part representserum albumin,a comparison ofthese
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bands between diabetic and normal mice mayrepresent the level ofthe diabetic
 
state. Although the differences listed in table3for bands 1 and2are not
 
supported statistically,the diabetic subjects appear to have a higher molecular
 
weightfor these bandsthan normal mice. Further investigation using alarger
 
sample size mightvalidate this finding and,ifso,mayserve as an additionalindex
 
ofdiabetic state. Results ofdeglycosylation with endoglycosidaseFconfirm that
 
both groups have the same relative mobility,indicating that they are modified by
 
mannose post-translatipnally and likely contain a homologous protein core.
 
Published reports have established a decrease in surfactant protein in typeI
 
diabetic rats compared with control subjects(40). While that study did not specify
 
whether the reduction wasin SP-A,B,or C,due to the fact that it was published
 
prior to standardization ofthe nomenclature,their reference was to a protein of
 
molecular weight 16kDa which mostlikely refers to either a dimericform ofSP-B
 
or a trimericform ofSP-C. The decreased amounts ofabsolute SP-A and SP-A
 
relative to totallavage proteinin diabetic versus normal mice in this studyjustify
 
these investigators'hypothesis that diabetes may alter pulmonary protein
 
metabolism,and provides new information regarding SP-Ain this model.
 
Thefunction ofSP-A appears to be the regulation oflipid transport to and
 
fi^ om type II pneumocytes(39). Since the function ofthe hpid components of
 
surfactant is known to be responsible in partfor reducing surface tension and
 
preventing alveolar collapse,a decrease in this protein might help explain reported
 
clinical abnormalities observed in diabetic patients such aslowerPa02and
 
reduced diffusion capacity(53)caused by altered lipid transport and turnover.
 
Theserum glucose assayfor mice treated with streptozotocin and vehicle
 
wasinconsistent as an indicator oftypeI diabetes. However,using serum albumin
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as an indicatpr ofdiabetic state,the increased molecule weights ofbands 1 and2
 
ofSTZ-treated versus vehicle-treated mice mayindicate that typeI diabetes was
 
presentand that the method used to determineserum glucose was notable to
 
confirm the presence ofthe induced disease. The similar results obtained for the
 
molecular weight characterizations ofBjthrough B4in type Iand type II diabetes
 
mayindicate that the increase in molecular weightofSP-A within each phenotype
 
was a result ofprotein glycation. Alternatively,the analysis ofserum insulin would
 
have allowed positive confirmation oftypeI diabetes;however,since this was not
 
done it was not possible to confirm or deny the presence ofinsulin-dependent
 
diabetes mellitus.
 
The results ofSDS-PAGEand immunoblotting for surfactant proteins B/C
 
showed that this antibody does recognize a protein or proteins in mouse lung
 
lavage presumed to be these surfactant proteins. However,since this antibody was
 
notspecific for one protein versus the other,an absolute differentiation between
 
the bandsidentified and the proteins was not possible. The molecular weightof
 
14kDafor thelower protein lies close to valuesfor SP-B and dimericSP-C
 
reported in other species(32,40,43-45). Therefore,this band mayrepresentan
 
altered form ofeither protein B or C. The larger(72kDa)molecular weight band
 
identifed may also represent an oligomericform ofeither SP-B or SP-C.
 
The difficulty in this study in isolating and characterizing mouse SP-B and
 
SP-C versus SP-A maybe accounted for by a variety ofcauses. Other investigators
 
have reported that SP-B and SP-C occur in very small quantites in lung lavage,and
 
this study indirectly confirms these reportsin that identification ofthese proteins
 
required the concentration ofentire lavage volumesforimmunostain resolution.
 
For this reason,larger volumes oflung lavage maybe necessary to further identify
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these proteins in this species. Additionally,the use ofBLOTTO asa primary
 
blocking agentfor the nitrocellulose and asa carrier for the anti-SP-B/C antibody
 
appeared to interfere with theimmunoblot procedure,as its use consistently
 
resulted in alack ofbanding. This may have been due to cross-reactivity between
 
the rabbit-anti-bovine SP-B/C antibody and the Bovine Lacto Transfer Technique
 
Optimizer(BLOTTO),in which the antibody wasbound in the milk preparation
 
and preventedfrom reacting with the nitrocellulose-complexed surfactant proteins.
 
The use ofa1%gelatin/TBS mixture as a replacementfor BLOTTO resulted in
 
banding ofSP-B/G duringimmunostaining,although variability in the success of
 
the process was still evident. This inconsistency maybe due to alow antibody
 
specificity towards mouse surfactant proteins. While the antibody was developed
 
in rabbit against bovine SP-B/C,no prior investigation had been done to
 
determine its effectivness inthe mouse.
 
Results ofSDS gels stained with CBB and immunostained by the available
 
heterologous antiserum on which mouse lung lavage wasrun showed the presence
 
ofprotein bands at molecular weights consistent with the expected location ofSP­
B and SP-Creported by other investigators. However,without specific antibody
 
confirmation, differentiating between mouse SP-B orSP-C was not possible.
 
Further characterization ofthese proteins will likely require the development of
 
homologous antiserum to mouse pulmonarylavage proteins.
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Chapters: Summary
 
The results ofthis study confirmed the presence ofSP-A,and identified
 
SP-B/Cin the C57BL/KsJ db/db and db/m mouse. SP-A was present as a
 
glycatedform,containing mannose and sialic acid moeities. Phenotypically,no
 
difference in molecular weightsfor SP-A wasfound between type I diabetic and
 
vehicle-treated mice,or between type 11 diabetic and normal mice. The relative
 
amountofSP-A wasless in type II diabetic animals thanin normal animals,
 
suggesting a possible cause for the observed alteration in lungfunction in diabetes
 
mellitus. Age-related increases for the molecular weights ofSP-A within the
 
phenotypes and treatment groups were presentand appeared to be caused by
 
protein glycosylation. Since glycosylation may adversely affect protein function,its
 
role in producing a decline in pulmonaryfunctionin aging warrantsfurther
 
investigation in diabetic as well as normalindividuals.
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